

Antisoma plc Annual Information Update

15 November 2006: In accordance with Prospectus Rule 5.2, London-based cancer drug developer Antisoma plc sets out below a list of the information that has been published or made available to the public over the previous sixteen months, up to and including 14 November 2006.

1. Announcements made via the Regulatory Information Service

All the announcements listed below can be obtained from the London Stock Exchange website, www.londonstockexchange.com/marketnews or from the Company's website www.antisoma.com

Time & Date	Title of Announcement
07:01 08-Nov-06	Positive data from Antisoma's AS1404 lung cancer trial presented at conference
13:00 02-Nov-06	Antisoma to present at Rodman and Renshaw Healthcare Conference on November 8
09:01 26-Oct-06	Annual report & accounts
15:58 19-Oct-06	Company Executive Incentive Plan grant
09:44 17-Oct-06	Antisoma to present at BIO InvestorForum on October 18
07:03 16-Oct-06	Antisoma presents positive tumour response data from AS1404 phase II trial in ovarian cancer
07:01 16-Oct-06	Antisoma's preliminary results for the year ended 30 June 2006
10:46 10-Oct-06	Notification of preliminary results - change of date
10:48 03-Oct-06	Payment of Directors' Fees in Shares
07:01 02-Oct-06	Antisoma announces positive phase I data on AS1411, plans phase II trials in renal and blood cancers
07:01 27-Sep-06	Final data from Antisoma's AS1404 lung cancer trial show clear survival benefit
07:01 18-Sep-06	Antisoma presents positive PSA data from AS1404 phase II trial in prostate cancer

07:01 12-Sep-06	Antisoma's AS1404 successfully combined with Erbitux in preclinical study
07:01 11-Sep-06	New data explain cancer cell killing by AS1402.
15:46 08-Sep-06	Holding(s) in Antisoma
07:01 05-Sep-06	Second dramatic response seen with Antisoma's AS1411 in renal cancer
07:01 29-Aug-06	Antisoma selects renal cancer and melanoma as phase I indications for AS1409
07:01 15-Aug-06	Antisoma update - progress on partnering and development of AS1404
13:01 04-Aug-06	Notification of Preliminary Results
09:34 31-Jul-06	Director shareholding
07:01 26-Jul-06	Director shareholding
07:01 19-Jul-06	Directors shareholdings

11:29 18-Jul-06	Directors shareholdings
14:09 12-Jul-06	Payment of Directors' Fees in Shares
12:01 22-Jun-06	Antisoma to present at Jeffries Life Sciences Conference on 27 June 2006
07:03 20-Jun-06	Antisoma to present at Piper Jaffray Health Care Conference
12:01 13-Jun-06	Antisoma to present at Needham & Company Fifth Annual Biotechnology Conference on 15 June 2006
09:05 13-Jun-06	Director/PDMR Shareholding
09:41 07-Jun-06	Director/PDMR Shareholding
09:09 07-Jun-06	Director/PDMR Shareholding
08:20 07-Jun-06	Director/PDMR Shareholding
16:15 06-Jun-06	Director/PDMR Shareholding
07:02 05-Jun-06	Antisoma's AS1404 shows early promise in ovarian cancer trial
07:02 05-Jun-06	Antisoma reports survival advantage for AS1404 in lung cancer and regains product rights

07:02 05-Jun-06	Antisoma announces positive phase I data, new trial plans and regaining of rights for R1550
13:43 10-May-06	Antisoma to present at the Rodman and Renshaw conference
07:01 02-May-06	Clinical data on Antisoma drugs AS1404 and R1550 to be presented at ASCO.
07:01 24-Apr-06	Antisoma appoints Dr Gary Acton as Chief Medical Officer
07:01 04-Apr-06	Positive preclinical data on Antisoma's AS1411 presented at AACR
16:19 03-Apr-06	Payment of Director's Fees in Shares
07:01 03-Apr-06	Antisoma's AS1404 enhances effectiveness of Avastin in colon and lung cancer models
07:01 20-Mar-06	Antisoma's phase II study of AS1404 in ovarian cancer completes recruitment
07:01 07-Mar-06	Antisoma to evaluate rainforest anti-cancer compounds from EcoBiotics Ltd
12:01 02-Mar-06	Antisoma to present at SG Cowen Conference on 6 March 2006

16:08 27-Feb-06	Company Share Option Plan and Executive Incentive Plan grants
07:01 22-Feb-06	Antisoma's AS1411 granted EU Orphan Drug Status for renal and pancreatic cancer
07:01 21-Feb-06	Antisoma plc reports half-year results
09:01 16-Feb-06	Notification of Interim Results
12:01 10-Feb-06	Antisoma to present at the BIO CEO conference
07:01 07-Feb-06	Antisoma plc appoints Piper Jaffray
07:02 06-Feb-06	Conference presentations highlight leading position of Antisoma's AS1404
13:15 06-Jan-06	Payment of Directors' Fees in Shares
16:11 14-Dec-05	Holding(s) in Company
15:04 09-Dec-05	Result of Annual General Meeting

09:31 09-Dec-05	Antisoma AGM update
13:16 06-Dec-05	Antisoma establishes Level One ADR (American Depositary Receipt) Program
07:01 06-Dec-05	Antisoma presents positive data on AS1409, expects trials to start mid-2006
07:01 16-Nov-05	Extended follow-up of renal cancer patients provides new support for Antisoma's AS1411
07:01 15-Nov-05	Antisoma's AS1404 whips up a cytokine storm to attack cancer
10:40 04-Nov-05	Annual Report and Accounts
12:13 02-Nov-05	Antisoma to present at the SG Cowen and Rodman & Renshaw healthcare conferences
07:01 01-Nov-05	Miscellaneous
11:45 24-Oct-05	Holding(s) in Company
11:57 18-Oct-05	Director Shareholding

07:01 17-Oct-05	Antisoma announces promising preliminary phase II data for AS1404 in lung cancer
15:51 13-Oct-05	Block listing
14:00 07-Oct-05	Holding(s) in Antisoma
15:50 06-Oct-05	Exercise of Options
12:28 06-Oct-05	Payment of Directors' Fees in Shares
09:54 22-Sep-05	Correct: Statement regarding company performance awards/share options
16:55 21-Sep-05	Statement re company performance awards/share options
09:30 21-Sep-05	Holding(s) in Company
07:01 15-Sep-05	Antisoma's preliminary results for the year ended 30 June 2005
07:01 14-Sep-05	Antisoma appoints Dale Boden as a Non-Executive Director

11:18 09-Sep-05	Full year/4th quarter financial results
07:01 06-Sep-05	Miscellaneous
07:01 01-Sep-05	Antisoma's AS1404 lung cancer study reaches recruitment target
07:01 17-Aug-05	Antisoma granted US orphan drug status for AS1411 in renal cancer
14:00 15-Aug-05	Holding(s) in Company
16:01 11-Aug-05	Holding(s) in Company
13:17 10-Aug-05	Holding(s) in Company
14:37 12-Jul-05	Antisoma releases Aptamera acquisition shares from escrow
12:48 11-Jul-05	Directors' Purchase of Shares and award of Matching Shares
12:52 08-Jul-05	Payment of Directors' Fees in Shares

2. Documents filed at Companies' House

Type	Date	Description
363s	19/09/2006	RETURN MADE UP TO 16/08/06; BULK LIST AVAILABLE SEPARATELY
88(2)R	16/08/2006	Issue of 57498 shares at £0.01 each on 21/07/06 increasing the issued share capital of the Company from 8040135 to 8039561
88(2)R	22/05/2006	Issue of 88533 shares at £0.01 each on 08/05/06 increasing the issued share capital of the Company from 8038676 to 8039561
88(2)R	28/04/2006	Issue of 45120 shares at £0.01 each on 03/04/06 increasing the issued share capital of the Company from 8038225 to 8038676
88(2)R	05/04/2006	Issue of 62938 shares at £0.01 each on 22/03/06 increasing the issued share capital of the Company from 8037596 to 8038225
88(2)R	05/04/2006	Issue of 79770 shares at £0.01 each on 21/03/06 increasing the issued share capital of the Company from 8036799 to 8037596
88(2)R	28/03/2006	Issue of 32189 shares at £0.01 each on 14/03/06 increasing the issued share capital of the Company from 8036478 to 8036799
88(2)R	28/03/2006	Issue of 17667 shares at £0.01 each on 10/03/06 increasing the issued share capital of the Company from 8036302 to 8036478
88(2)R	21/03/2006	Issue of 41953 shares at £0.01 each on 01/03/06 increasing the issued share capital of the Company from 8035883 to 8036302
88(2)R	08/03/2006	Issue of 15185 shares at £0.01 each on 20/02/06 increasing the issued share capital from 8035732 to 8035883
88(2)R	27/02/2006	Issue of 464663 shares at £0.01 each on 08/02/06 increasing the share capital of the Company from 8031086 to 8035732
88(2)R	14/02/2006	Issue of 83569 shares at £0.01 each on 24/01/06 increasing the share capital of the Company from 8030251 to 8031086
88(2)R	30/01/2006	Issue of 32212 shares at £0.01 each on 18/01/06 increasing the share capital of the Company from 8029929 to 8030251
88(2)R	19/01/2006	Issue of 96540 shares at £0.01 each on 05/01/06 increasing the share capital of the Company from 8028964 to 8029929
AA	04/01/2006	GROUP OF COMPANIES' ACCOUNTS MADE UP TO 30/06/05
88(2)R	04/01/2006	Issue of 69179 shares at £0.01 each on 13/12/05 increasing the share capital of the Company from 8028273 to 8028964
88(2)R	21/12/2005	Issue of 33600000 shares at £0.01 each on 08/12/05 increasing the share capital of the Company from 7692273 to 8028273
88(2)R	21/12/2005	Issue of 383347 shares at £0.01 each on 30/11/05 increasing the share capital of the Company from 7688440 to 7692273
88(2)R	07/12/2005	Issue of 1355506 shares at £0.01 each on 11/07/05
88(2)R	07/12/2005	Issue of 301923 shares at £0.01 each on 19/10/05 increasing the share capital of the Company from 7685421 to 7688440
88(2)R	07/12/2005	Issue of 29544 shares at £0.01 each on 10/10/05 increasing the share capital of the Company from 7685126 to 7685421
88(2)R	07/12/2005	Issue of 73115 shares at £0.01 each on 20/10/05 increasing the share capital of the Company from 7684395 to 7685126
88(2)R	07/12/2005	Issue of 162580 shares at £0.01 each on 25/10/05 increasing the share capital of the Company from 7682770 to 7684395
88(2)R	07/12/2005	Issue of 47203 shares at £0.01 each on 27/10/05 increasing the share capital from 7682298 to 7682770
88(2)R	07/12/2005	Issue of 857531 shares at £0.01 each on 05/10/05 increasing the

